Literature DB >> 12800730

Vertebral fractures in boys with Duchenne muscular dystrophy.

J E Bothwell1, K E Gordon, J M Dooley, J MacSween, E A Cummings, S Salisbury.   

Abstract

Osteoporosis causes significant morbidity for boys with Duchenne muscular dystrophy. Corticosteroid therapy given to prolong mobility may increase the rate of osteoporosis and risk of fracture. This study of 33 boys with Duchenne muscular dystrophy determined retrospectively the incidence of vertebral fractures particularly after initiation of corticosteroids. A latency period of 40 months after commencement of steroids occurred before the first vertebral fracture appeared. However, by 100 months of treatment approximately 75% had sustained a vertebral fracture.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12800730     DOI: 10.1177/000992280304200408

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  21 in total

1.  Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment.

Authors:  M L Bianchi; L Morandi; E Andreucci; S Vai; J Frasunkiewicz; R Cottafava
Journal:  Osteoporos Int       Date:  2010-05-11       Impact factor: 4.507

2.  Prednisolone treatment and restricted physical activity further compromise bone of mdx mice.

Authors:  S A Novotny; G L Warren; A S Lin; R E Guldberg; K A Baltgalvis; D A Lowe
Journal:  J Musculoskelet Neuronal Interact       Date:  2012-03       Impact factor: 2.041

3.  Current treatment and management of dystrophinopathies.

Authors:  Nathalie Goemans; Gunnar Buyse
Journal:  Curr Treat Options Neurol       Date:  2014-05       Impact factor: 3.598

4.  Fractures and Linear Growth in a Nationwide Cohort of Boys With Duchenne Muscular Dystrophy With and Without Glucocorticoid Treatment: Results From the UK NorthStar Database.

Authors:  Shuko Joseph; Cunyi Wang; Kate Bushby; Michaela Guglieri; Iain Horrocks; Volker Straub; S Faisal Ahmed; Sze Choong Wong
Journal:  JAMA Neurol       Date:  2019-06-01       Impact factor: 18.302

5.  The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy.

Authors:  A M Sbrocchi; F Rauch; P Jacob; A McCormick; H J McMillan; M A Matzinger; L M Ward
Journal:  Osteoporos Int       Date:  2012-11       Impact factor: 4.507

6.  Insights into bone health in Duchenne muscular dystrophy.

Authors:  Victor H Morgenroth; Lauren P Hache; Paula R Clemens
Journal:  Bonekey Rep       Date:  2012-02-01

Review 7.  Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.

Authors:  Jennifer M Bell; Michael D Shields; Janet Watters; Alistair Hamilton; Timothy Beringer; Mark Elliott; Rosaline Quinlivan; Sandya Tirupathi; Bronagh Blackwood
Journal:  Cochrane Database Syst Rev       Date:  2017-01-24

8.  Dystrophin and utrophin "double knockout" dystrophic mice exhibit a spectrum of degenerative musculoskeletal abnormalities.

Authors:  Christian Isaac; Adam Wright; Arvydas Usas; Hongshuai Li; Ying Tang; Xiaodong Mu; Nicholas Greco; Qing Dong; Nam Vo; James Kang; Bing Wang; Johnny Huard
Journal:  J Orthop Res       Date:  2012-10-23       Impact factor: 3.494

9.  Official positions of the International Society for Clinical Densitometry (ISCD) on DXA evaluation in children and adolescents.

Authors:  Maria Luisa Bianchi; Sanford Baim; Nick J Bishop; Catherine M Gordon; Didier B Hans; Craig B Langman; Mary B Leonard; Heidi J Kalkwarf
Journal:  Pediatr Nephrol       Date:  2009-07-15       Impact factor: 3.714

10.  Black bear parathyroid hormone has greater anabolic effects on trabecular bone in dystrophin-deficient mice than in wild type mice.

Authors:  Sarah K Gray; Meghan E McGee-Lawrence; Jennifer L Sanders; Keith W Condon; Chung-Jui Tsai; Seth W Donahue
Journal:  Bone       Date:  2012-05-11       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.